주사용 생리식염수 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of normal saline for parenteral use Market

The global normal saline for parenteral use market is witnessing steady growth, driven by the increasing demand for intravenous fluids in hospitals for conditions such as dehydration, electrolyte imbalance, sepsis, hemorrhage, and wound dressing. According to Fortune Business Insights, the market was valued at USD 3.91 billion in 2025 and is projected to grow to USD 4.17 billion in 2026, ultimately reaching USD 7.15 billion by 2034, reflecting a CAGR of 6.97% during 2026-2034. North America dominated the market in 2025 with a 39.46% share, largely due to the high uptake of 0.9% sodium chloride solutions and strategic investments by key players to expand production capacity.

Normal saline (0.9% sodium chloride) is one of the most commonly used crystalloid fluids, particularly recommended by the Surviving Sepsis Campaign (SSC) for fluid resuscitation in septic shock. The rising incidence of neonatal sepsis globally-diagnosed in 1 to 50 per 1,000 live births annually-further boosts demand for normal saline. Increasing hospital admissions, geriatric populations, and government guidelines recommending saline in critical care are additional growth drivers.

COVID-19 Impact

The COVID-19 pandemic had a temporary negative impact on market growth due to postponed elective surgeries and reduced hospital admissions. Over 28 million elective surgeries were canceled globally during the peak disruption, and organizations like ICU Med reported a 10.3% revenue decrease for IV solutions in the first half of 2020. Despite this setback, post-pandemic recovery and an increased focus on healthcare infrastructure have allowed the market to resume its growth trajectory.

Market Trends

Demand for normal saline spikes during flu seasons, particularly with severe strains such as H3N2. For example, the European Union reported up to 50 million influenza infections annually, driving hospitalizations and saline use. Similarly, the U.S. experienced 490,561 hospital admissions during the 2018-2019 flu season. These trends highlight the critical role of normal saline in patient hydration and medication delivery.

Market Growth Factors

1. Rising Use in Critical Care: Saline is essential for managing dehydration, vomiting, diarrhea, and fluid resuscitation in ICU and NICU settings. Approximately 200 million liters of saline are sold annually in the U.S., while over 1 million liters are administered globally each day.

2. Hospital Admissions and Surgeries: Growing numbers of in-patients and surgical procedures further fuel demand, as intravenous therapy is a standard component of hospital care. For instance, the NHS reports over 5 million acute hospital admissions annually, many requiring IV saline.

3. Government Guidelines: Recommendations from bodies such as the European Society of Intensive Care Medicine (ESICM) support the widespread use of saline in critical care, strengthening market adoption.

Restraining Factors

The market faces challenges due to the shift toward balanced IV fluids. Studies indicate that balanced solutions reduce mortality and kidney damage compared to normal saline, influencing hospital adoption. For example, a Vanderbilt University study found one fewer death or severe kidney complication per 100 patients administered balanced fluids.

Market Segmentation

By Type:

• Plastic Bottles: Dominant segment, expected to hold 89.33% of the market in 2026, due to breakage prevention and easier distribution.
• Glass Bottles: Offers lower contamination risk and environmental benefits; projected to grow steadily.

By Application:

• Intravenous Injection: Largest share (97.45% in 2026) due to being the preferred administration route.
• Intramuscular Injection: Expected to grow steadily due to ease of administration and low invasiveness.

By Region:

• North America: Largest market, USD 1.54 billion in 2025, rising to USD 1.65 billion in 2026, with the U.S. projected at USD 1.57 billion in 2026.
• Asia Pacific: Significant growth due to rising hospital admissions, geriatric population, and sepsis prevalence; Japan at USD 0.7 billion, China and India at USD 0.08 billion each in 2026.
• Europe: Driven by government support and recommendations; UK at USD 0.08 billion, Germany at USD 0.11 billion in 2026.
• Rest of the World: Moderate growth in Latin America and Middle East & Africa due to improving healthcare infrastructure.

Key Players

Major companies shaping the market include Baxter (U.S.), Kelun Group (China), B. Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), ICU Medical (U.S.), among others. These firms focus on R&D, strategic collaborations, and production capacity expansion. For example, in August 2022, Assure Infusions announced a fully automated IV fluids plant in Florida to meet high U.S. demand.

Conclusion

The global normal saline for parenteral use market is set for consistent growth, expanding from USD 3.91 billion in 2025 to USD 7.15 billion by 2034, driven by increasing hospitalizations, surgical procedures, sepsis incidence, and supportive government guidelines. Despite challenges from the shift to balanced fluids, innovations in packaging, distribution, and production capacity, along with rising demand across North America, Europe, and Asia Pacific, are expected to sustain market growth and ensure the widespread availability of saline for critical care applications globally.

Segmentation By Type

• Plastic Bottles
• Glass Bottles

By Application

• Intramuscular injection
• Intravenous injection

By Geography

• North America (By Type, Application, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, and Country)
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific (By Type, Application, and Country)
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Rest of the Asia Pacific
• Latin America (By Type, Application, and Country)
  • Mexico
  • Brazil
  • Colombia
  • Argentina
  • Rest of Latin America
• Middle East & Africa (By Type, Application, and Country)
  • Turkey
  • Saudi Arabia
  • UAE
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Number of Hospital Admissions, By Key Countries/Regions, 2025
• 4.2. Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. Impact of COVID-19 on the Market

5. Global Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Plastic Bottles
  • 5.1.2. Glass Bottles
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Intramuscular Injection
  • 5.2.2. Intravenous Injection
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Plastic Bottles
  • 6.1.2. Glass Bottles
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Intramuscular Injection
  • 6.2.2. Intravenous Injection
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Plastic Bottles
  • 7.1.2. Glass Bottles
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Intramuscular Injection
  • 7.2.2. Intravenous Injection
• 7.3. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Russia
  • 7.3.6. Rest of Europe

8. Asia Pacific Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Plastic Bottles
  • 8.1.2. Glass Bottles
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Intramuscular Injection
  • 8.2.2. Intravenous Injection
• 8.3. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. South Korea
  • 8.3.6. Taiwan
  • 8.3.7. Indonesia
  • 8.3.8. Thailand
  • 8.3.9. Malaysia
  • 8.3.10. Rest of Asia Pacific

9. Latin America Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Plastic Bottles
  • 9.1.2. Glass Bottles
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Intramuscular Injection
  • 9.2.2. Intravenous Injection
• 9.3. Market Analysis, Insights and Forecast - By Countries/ Sub regions
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Colombia
  • 9.3.4. Argentina
  • 9.3.5. Rest of Latin America

10. Middle East & Africa Normal Saline for Parenteral Use Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Plastic Bottles
  • 10.1.2. Glass Bottles
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Intramuscular Injection
  • 10.2.2. Intravenous Injection
• 10.3. Market Analysis, Insights and Forecast - By Countries/ Sub region
  • 10.3.1. Turkey
  • 10.3.2. Saudi Arabia
  • 10.3.3. UAE
  • 10.3.4. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Baxter
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT analysis
    • 11.2.1.4. Recent developments
    • 11.2.1.5. strategies
    • 11.2.1.6. financials (based on availability)
  • 11.2.2. Kelun Group
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT analysis
    • 11.2.2.4. Recent developments
    • 11.2.2.5. strategies
    • 11.2.2.6. financials (based on availability)
  • 11.2.3. B. Braun Melsungen AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT analysis
    • 11.2.3.4. Recent developments
    • 11.2.3.5. strategies
    • 11.2.3.6. financials (based on availability)
  • 11.2.4. Fresenius Kabi AG
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT analysis
    • 11.2.4.4. Recent developments
    • 11.2.4.5. strategies
    • 11.2.4.6. financials (based on availability)
  • 11.2.5. SSY Group Limited
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT analysis
    • 11.2.5.4. Recent developments
    • 11.2.5.5. strategies
    • 11.2.5.6. financials (based on availability)
  • 11.2.6. ICU Medical
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT analysis
    • 11.2.6.4. Recent developments
    • 11.2.6.5. strategies
    • 11.2.6.6. financials (based on availability)
  • 11.2.7. Double-Crane Pharmaceutical Co., Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT analysis
    • 11.2.7.4. Recent developments
    • 11.2.7.5. strategies
    • 11.2.7.6. financials (based on availability)
  • 11.2.8. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT analysis
    • 11.2.8.4. Recent developments
    • 11.2.8.5. strategies
    • 11.2.8.6. financials (based on availability)
  • 11.2.9. Cisen Pharmaceutical Co., Ltd.
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT analysis
    • 11.2.9.4. Recent developments
    • 11.2.9.5. strategies
    • 11.2.9.6. financials (based on availability)
  • 11.2.10. Pharmally International Holding Co., Ltd.
    • 11.2.10.1. Overview
    • 11.2.10.2. Product
    • 11.2.10.3. SWOT analysis
    • 11.2.10.4. Recent developments
    • 11.2.10.5. strategies
    • 11.2.10.6. financials (based on availability)
  • 11.2.11. Other Prominent Players